Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.67 |
| ▸ | APP | P05067 | 4/20 | 0.67 |
| ▸ | SNCA | P37840 | 4/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.54 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.54 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 5/20 | 0.51 |
| ▸ | RARA | P10276 | 4/20 | 0.51 |
| ▸ | RARB | P10826 | 4/20 | 0.51 |
| ▸ | RARG | P13631 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878712 | 1.00 | MAPT (0.87) | MAPTALOX15ALDH1A1CYP3A4APP | |
| Canthaxanthin SCHEMBL19618 | 0.93 | MAPT (1.00) | MAPTALOX15ALDH1A1CYP3A4APP | |
| Canthaxanthin SCHEMBL12920083 | 0.93 | MAPT (1.00) | MAPTALOX15ALDH1A1CYP3A4APP | |
| Canthaxanthin SCHEMBL8971840 | 0.93 | MAPT (1.00) | MAPTALOX15ALDH1A1CYP3A4APP | |
| SCHEMBL8128019 | 0.91 | MAPT (0.90) | MAPTALOX15ALDH1A1CYP3A4APP | |
| SCHEMBL8132702 | 0.91 | MAPT (0.90) | MAPTALOX15ALDH1A1CYP3A4APP | |
| SCHEMBL13252665 | 0.91 | MAPT (0.90) | MAPTALOX15ALDH1A1CYP3A4APP | |
| SCHEMBL2832602 | 0.90 | MAPT (0.92) | MAPTALOX15ALDH1A1CYP3A4APP | |
| SCHEMBL7759851 | 0.88 | MAPT (0.85) | MAPTALOX15ALDH1A1CYP3A4APP | |
| Canthaxanthin SCHEMBL419514 | 0.88 | MAPT (0.90) | MAPTALOX15ALDH1A1CYP3A4APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167647-A2 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090304614-A1 | Use of Polyunsaturated Compounds as Whitening Agents | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2009-12-10 | — | — | US | claimed |
| US-20090136470-A1 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | claimed |
| WO-2008157394-A2 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2008-12-24 | — | — | WO | claimed |
| US-20060281813-A1 | Methods of treating hyperproliferative cell disorders | RUBIN CHARLES | 2006-12-14 | — | — | US | claimed |
| EP-1628631-A2 | METHODS OF TREATING HYPERPROLIFERATIVE CELL DISORDERS | Achkar, Charles C. (US) | 2006-03-01 | — | — | EP | claimed |
| EP-1104294-B8 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | LEO PHARMA AS (DK) | 2005-11-23 | — | — | EP | claimed |
| EP-1104294-B1 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | LEO PHARMA A S (DK) | 2005-09-28 | — | — | EP | claimed |
| WO-2005000230-A2 | METHODS OF TREATING HYPERPROLIFERATIVE CELL DISORDERS | ACHKAR CHARLES (US) | 2005-01-06 | — | — | WO | claimed |
| US-6552009-B2 | Vitamin D analog and a retinoid, wherein: the retinoid is 4-oxo-retinol, 4-oxo- retinal, or 4-oxo-retinyl ester; also restoring the natural color of gray hair; treating hair and skin disorders | GENTRIX LLC | 2003-04-22 | — | — | US | claimed |
| EP-1104294-A4 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | GENTRIX LLC (US) | 2003-02-05 | — | — | EP | claimed |
| US-20020183388-A1 | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-05 | — | — | US | claimed |
| WO-2002060430-A1 | USE OF RETINOIDS PLUS HISTONE DEACETYLASE INHIBITORS TO INHIBIT THE GROWTH OF SOLID TUMORS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2002-08-08 | — | — | WO | claimed |
| WO-2002050022-A1 | PROCESS FOR THE PRODUCTION OF CAROTENOIDS | ADISSEO FRANCE S.A.S. (FR) | 2002-06-27 | — | — | WO | claimed |
| EP-1216990-A1 | Process for the preparation of carotenoids | AVENTIS ANIMAL NUTRITION S.A. (FR) | 2002-06-26 | — | — | EP | claimed |
| US-20010049365-A1 | Vitamin D analog and a retinoid, wherein: the retinoid is 4-oxo-retinol, 4-oxo- retinal, or 4-oxo-retinyl ester; also restoring the natural color of gray hair; treating hair and skin disorders | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2001-12-06 | — | — | US | claimed |
| EP-1104294-A1 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | Achkar, Charles C. (US) | 2001-06-06 | — | — | EP | claimed |
| WO-2000003700-A1 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | ACHKAR CHARLES C (US) | 2000-01-27 | — | — | WO | claimed |
| US-5962534-A | ACNE THERAPY | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-10-05 | — | — | US | claimed |
| US-20250109422-A1 | YARROWIA PRODUCTION PROCESS | DSM IP ASSETS B.V. (NL) | 2025-04-03 | — | — | US | disclosed |
| EP-4473099-A1 | YARROWIA PRODUCTION PROCESS | DSM IP Assets B.V. (NL) | 2024-12-11 | — | — | EP | disclosed |
| US-20240058293-A1 | Nutritional Formulas Comprising Medium Chain Fatty Acids or Esters Thereof and Methods Related Thereto | UNIV EMORY (US) | 2024-02-22 | — | — | US | disclosed |
| US-11826336-B2 | Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto | EMORY UNIVERSITY (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023215458-A1 | COMPOSITIONS AND METHODS FOR SLOWING DOWN AGING AND EXTENDING LIFESPAN | AGELESS SCIENCES, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023148187-A1 | YARROWIA PRODUCTION PROCESS | DSM IP ASSETS B.V. (NL) | 2023-08-10 | — | — | WO | disclosed |
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-4074695-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2022-10-19 | — | — | EP | disclosed |
| US-20210283090-A1 | Nutritional Formulas Comprising Medium Chain Fatty Acids or Esters Thereof and Methods Related Thereto | UNIV EMORY (US) | 2021-09-16 | — | — | US | disclosed |
| CN-107266345-B | (hetero) arylcyclopropylamine compounds as LSD1 inhibitors | 奥瑞泽恩基因组学股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-11026913-B2 | Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto | EMORY UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| US-10765653-B2 | Fatty acid formulations and methods of use thereof | CHILDREN'S HOSPITAL & RESEARCH CENTER OAKLAND (US) | 2020-09-08 | — | — | US | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| US-20190328696-A1 | FATTY ACID FORMULATIONS AND METHODS OF USE THEREOF | CHILDREN'S HOSPITAL & RESEARCH CENTER OAKLAND | 2019-10-31 | — | — | US | disclosed |
| EP-3539560-A1 | FATTY ACID FORMULATIONS AND METHODS OF USE THEREOF | Children's Hospital & Research Center at Oakland (US) | 2019-09-18 | — | — | EP | disclosed |
| US-10398671-B2 | Fatty acid formulations and methods of use thereof | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2019-09-03 | — | — | US | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| EP-3495349-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2019-06-12 | — | — | EP | disclosed |
| US-10300034-B2 | Fatty acid formulations and methods of use thereof | CHILDREN'S HOSPITAL OF OAKLAND RESEARCH INSTITUTE (US) | 2019-05-28 | — | — | US | disclosed |
| EP-2131679-B1 | FATTY ACID FORMULATIONS AND METHODS OF USE THEREOF | CHILDRENS HOSPITAL & RES CENTER AT OAKLAND (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-2776394-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-12-26 | — | — | EP | disclosed |
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2018-12-13 | — | — | US | disclosed |
| WO-2018219478-A1 | HETEROARYL-CARBOXAMIDES AS HISTONE DEMETHYLASE INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018149986-A1 | 2-(BICYCLO-HETEROARYL)-ISONICOTINIC DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2018-08-23 | — | — | WO | disclosed |
| US-9944601-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2018-04-17 | — | — | US | disclosed |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-03-22 | — | — | US | disclosed |
| US-9687016-B2 | Fatty acid formulations and methods of use thereof | CHILDREN'S HOSPITAL & RESEARCH CENTER OAKLAND (US) | 2017-06-27 | — | — | US | disclosed |
| US-9670136-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2017-06-06 | — | — | US | disclosed |
| US-20170143655-A1 | FATTY ACID FORMULATIONS AND METHODS OF USE THEREOF | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND | 2017-05-25 | — | — | US | disclosed |
| CN-103958474-B | (hetero) arylcyclopropylamine compounds as LSD1 inhibitors | 奥莱松基因组股份有限公司 | 2017-03-08 | — | — | CN | disclosed |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2017-01-12 | — | — | US | disclosed |
| US-20160368857-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2016-12-22 | — | — | US | disclosed |
| US-9487512-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2016-11-08 | — | — | US | disclosed |
| US-9469597-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2016-10-18 | — | — | US | disclosed |
| US-20160199337-A1 | Nutritional Formulas Comprising Medium Chain Fatty Acids or Esters Thereof and Methods Related Thereto | CHILDREN'S HEALTHCARE OF ATLANTA, INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-9359322-B2 | C-linked glucuronide of N-(4-hydroxybenzyl) retinone, analogs thereof, and methods of using the same to inhibit neoplastic cell growth | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-9061040-B2 | Combination therapy for breast cancer | CIUSTEA MIHAI (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150094277-A1 | Combination therapy and methods for treatment and prevention of hyperproliferative diseases | CIUSTEA MIHAI (US) | 2015-04-02 | — | — | US | disclosed |
| WO-2015034984-A1 | NUTRITIONAL FORMULAS COMPRISING MEDIUM CHAIN FATTY ACIDS OR ESTERS THEREOF AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-01-22 | — | — | US | disclosed |
| EP-2776394-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2014-09-17 | — | — | EP | disclosed |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2014-09-11 | — | — | US | disclosed |
| EP-2768805-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2014-08-27 | — | — | EP | disclosed |
| US-8697350-B2 | Biomarker combinations for colorectal cancer | DIAGNOPLEX (CH) | 2014-04-15 | — | — | US | disclosed |
| US-8481011-B2 | Use of polyunsaturated compounds as whitening agents | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2013-07-09 | — | — | US | disclosed |
| WO-2013057322-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013057320-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2013-04-25 | — | — | WO | disclosed |
| US-20130045179-A1 | Combination therapy and methods for treatment and prevention of hyperproliferative diseases | CIUSTEA MIHAI (US) | 2013-02-21 | — | — | US | disclosed |
| EP-2544006-A1 | Biomarker combinations for colorectal cancer | Diagnoplex (CH) | 2013-01-09 | — | — | EP | disclosed |
| US-20120190737-A1 | Fatty Acid Formulations and Methods of Use Thereof | CHILDREN'S HOSPITAL & RESEARCH CENTER OAKLAND | 2012-07-26 | — | — | US | disclosed |
| WO-2012071469-A2 | HISTONE DEMETHYLASE INHIBITORS AND USES THEREOF FOR TREATMENT O F CANCER | NEVADA CANCER INSTITUTE (US) | 2012-05-31 | — | — | WO | disclosed |
| US-8026220-B2 | C-linked glucuronide of N-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110212906-A1 | C-LINKED GLUCURONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHODS OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 2011-09-01 | — | — | US | disclosed |
| US-20100330079-A1 | BIOMARKDER COMBINATIONS FOR COLORECTAL CANCER | BIOPÔLE IV (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-1576144-B1 | PROTEORHODOPSIN MUTANTS WITH IMPROVED OPTICAL CHARACTERISTICS | GENENCOR INT (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20100113392-A1 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING MULTIPLE MYELOMA | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| EP-2171470-A2 | BIOMARKER COMBINATIONS FOR COLORECTAL CANCER | Diagnoplex (CH) | 2010-04-07 | — | — | EP | disclosed |
| EP-2167647-A2 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2131679-A1 | FATTY ACID FORMULATIONS AND METHODS OF USE THEREOF | Children's Hospital & Research Center at Oakland (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090304614-A1 | Use of Polyunsaturated Compounds as Whitening Agents | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2009-12-10 | — | — | US | disclosed |
| US-20090247549-A1 | Methods of using saha and bortezomib for treating cancer | SCHERING CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090227674-A1 | Combination methods fo saha and targretin for treating cancer | MERCK SHARP & DOHME CORP. | 2009-09-10 | — | — | US | disclosed |
| US-20090215706-A1 | C-LINKED GLUCURONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHOD OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 2009-08-27 | — | — | US | disclosed |
| EP-2086323-A2 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING MULTIPLE MYELOMA | University Of Maryland, Baltimore (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090136470-A1 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | disclosed |
| US-20090118483-A1 | Light-driven energy generation using proteorhodopsin | MONTEREY BAY AQUARIUM RESEARCH INSTITUTE | 2009-05-07 | — | — | US | disclosed |
| US-7528114-B2 | C-linked glucuronide of N-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20090105329-A1 | Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies | NATIONAL INSTITUTES OF HEALTH (DEITR) | 2009-04-23 | — | — | US | disclosed |
| WO-2009037572-A2 | BIOMARKER COMBINATIONS FOR COLORECTAL CANCER | DIAGNOPLEX (CH) | 2009-03-26 | — | — | WO | disclosed |
| US-7501488-B2 | Proteorhodopsin mutants with improved optical characteristics | GENENCOR INTERNATIONAL, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| CN-101365440-A | Methods of treating cancer with SAHA, carboplatin, and paclitaxel, and other combination therapies | MERCK & CO INC (US) | 2009-02-11 | — | — | CN | disclosed |
| WO-2008157394-A2 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2008-12-24 | — | — | WO | disclosed |
| CN-101325955-A | Methods of treating cancer with SAHA and pemetrexed | MERCK & CO INC (US) | 2008-12-17 | — | — | CN | disclosed |
| CN-101300015-A | Method of using SAHA and Erlotinib for treating cancer | MERCK & CO INC (US) | 2008-11-05 | — | — | CN | disclosed |
| US-20080269182-A1 | Method of treating cancers with SAHA and Pemetrexed | PLUDA JAMES | 2008-10-30 | — | — | US | disclosed |
| EP-1973610-A1 | USE OF POLYUNSATURATED COMPOUNDS AS WHITENING AGENTS | Pierre Fabre Dermo-Cosmetique (FR) | 2008-10-01 | — | — | EP | disclosed |
| US-20080221138-A1 | Method of using SAHA and Erlotinib for treating cancer | MERCK SHARP & DOHME CORP. | 2008-09-11 | — | — | US | disclosed |
| US-20080213239-A1 | Dietary mixture comprising docosohexaenoic acid, alpha -tocopherol, gamma tocopherol and eicosapentaenoic acid for use in treatment and prevention of inflammatory, rheumatic and cardiovascular disorders | CHILDREN'S HOSPITAL OF OAKLAND RESEARCH INSTITUTE | 2008-09-04 | — | — | US | disclosed |
| WO-2008103370-A1 | FATTY ACID FORMULATIONS AND METHODS OF USE THEREOF | CHILDREN'S HOSPITAL AND RESEARCH CENTER AT OAKLAND (US) | 2008-08-28 | — | — | WO | disclosed |
| EP-1954284-A1 | METHOD OF TREATING CANCERS WITH SAHA AND PEMETREXED | Merck and Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1947936-A2 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING CANCER | Merck and Co., Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1942907-A2 | METHODS OF USING SAHA AND ERLOTINIB FOR TREATING CANCER | Merck and Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1942884-A2 | METHODS OF TREATING CANCERS WITH SAHA, CARBOPLATIN, AND PACLITAXEL AND OTHER COMBINATION THERAPIES | Merck and Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1933825-A2 | COMBINATION METHODS OF SAHA AND TARGRETIN FOR TREATING CANCER | Merck and Co., Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008057456-A2 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING MULTIPLE MYELOMA | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1891085-A2 | C-LINKED GLUCORONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHOD OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070197473-A1 | Methods of using SAHA and Bortezomib for treating cancer | MERCK & CO., INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197568-A1 | Methods of using SAHA and Erlotinib for treating cancer | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-08-23 | — | — | US | disclosed |
| US-7253268-B2 | Light-driven energy generation using proteorhodopsin | MONTEREY BAY AQUARIUM RESEARCH INSTITUTE (US) | 2007-08-07 | — | — | US | disclosed |
| WO-2007068743-A1 | USE OF POLYUNSATURATED COMPOUNDS AS WHITENING AGENTS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2007-06-21 | — | — | WO | disclosed |
| US-20070117815-A1 | Method of treating cancers with SAHA and pemetrexed | MERCK & CO., INC. | 2007-05-24 | — | — | US | disclosed |
| WO-2007056135-A1 | METHOD OF TREATING CANCERS WITH SAHA AND PEMETREXED | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056244-A2 | METHODS OF USING SAHA AND ERLOTINIB FOR TREATING CANCER | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056162-A2 | METHODS OF TREATING CANCERS WITH SAHA, CARBOPLATIN, AND PACLITAXEL AND OTHER COMBINATION THERAPIES | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056232-A2 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING CANCER | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007022408-A2 | COMBINATION METHODS OF SAHA AND TARGRETIN FOR TREATING CANCER | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1576144-A4 | PROTEORHODOPSIN MUTANTS WITH IMPROVED OPTICAL CHARACTERISTICS | GENENCOR INT (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060287255-A1 | C-linked glucuronide of N-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 2006-12-21 | — | — | US | disclosed |
| US-20060281813-A1 | Methods of treating hyperproliferative cell disorders | RUBIN CHARLES | 2006-12-14 | — | — | US | disclosed |
| WO-2006119402-A2 | C-LINKED GLUCORONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHOD OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1628631-A2 | METHODS OF TREATING HYPERPROLIFERATIVE CELL DISORDERS | Achkar, Charles C. (US) | 2006-03-01 | — | — | EP | disclosed |
| EP-1337552-A4 | LIGHT-DRIVEN ENERGY GENERATION USING PROTEORHODOPSIN | MONTEREY BAY AQUARIUM RES INST (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1104294-B8 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | LEO PHARMA AS (DK) | 2005-11-23 | — | — | EP | disclosed |
| EP-1104294-B1 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | LEO PHARMA A S (DK) | 2005-09-28 | — | — | EP | disclosed |
| EP-1576144-A2 | PROTEORHODOPSIN MUTANTS WITH IMPROVED OPTICAL CHARACTERISTICS | GENENCOR INTERNATIONAL, INC. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050095605-A1 | Proteorhodopsin mutants with improved optical characteristics | DANISCO US INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005000230-A2 | METHODS OF TREATING HYPERPROLIFERATIVE CELL DISORDERS | ACHKAR CHARLES (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004063326-A2 | PROTEORHODOPSIN MUTANTS WITH IMPROVED OPTICAL CHARACTERISTICS | GENENCOR INTERNATIONAL, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20030219866-A1 | Stem cell-like cells | FORNIX BIOSCIENCES N.V. (NL) | 2003-11-27 | — | — | US | disclosed |
| US-20030207848-A1 | Compositions and methods of treating abnormal cell proliferation | GENTRIX LLC | 2003-11-06 | — | — | US | disclosed |
| EP-1337552-A2 | LIGHT-DRIVEN ENERGY GENERATION USING PROTEORHODOPSIN | Monterey Bay Aquarium Research Institute (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030104375-A1 | Light-driven energy generation using proteorhodopsin | MONTEREY BAY AQUARIUM RESEARCH INSTITUTE | 2003-06-05 | — | — | US | disclosed |
| US-6552009-B2 | Vitamin D analog and a retinoid, wherein: the retinoid is 4-oxo-retinol, 4-oxo- retinal, or 4-oxo-retinyl ester; also restoring the natural color of gray hair; treating hair and skin disorders | GENTRIX LLC | 2003-04-22 | — | — | US | disclosed |
| EP-1301590-A2 | STEM CELL-LIKE CELLS | Fornix Biosciences N.V. (NL) | 2003-04-16 | — | — | EP | disclosed |
| EP-1104294-A4 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | GENTRIX LLC (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20020183388-A1 | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-05 | — | — | US | disclosed |
| WO-2002060430-A1 | USE OF RETINOIDS PLUS HISTONE DEACETYLASE INHIBITORS TO INHIBIT THE GROWTH OF SOLID TUMORS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002050022-A1 | PROCESS FOR THE PRODUCTION OF CAROTENOIDS | ADISSEO FRANCE S.A.S. (FR) | 2002-06-27 | — | — | WO | disclosed |
| EP-1216990-A1 | Process for the preparation of carotenoids | AVENTIS ANIMAL NUTRITION S.A. (FR) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002008388-A2 | STEM CELL-LIKE CELLS | FORNIX BIOSCIENCES N.V. (NL) | 2002-01-31 | — | — | WO | disclosed |
| EP-1176189-A1 | Stem cell-like cells | Fornix Biosciences N.V. (NL) | 2002-01-30 | — | — | EP | disclosed |
| US-20010049365-A1 | Vitamin D analog and a retinoid, wherein: the retinoid is 4-oxo-retinol, 4-oxo- retinal, or 4-oxo-retinyl ester; also restoring the natural color of gray hair; treating hair and skin disorders | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2001-12-06 | — | — | US | disclosed |
| WO-2001083701-A2 | LIGHT-DRIVEN ENERGY GENERATION USING PROTEORHODOPSIN | MONTEREY BAY AQUARIUM RESEARCH INSTITUTE (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-1104294-A1 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | Achkar, Charles C. (US) | 2001-06-06 | — | — | EP | disclosed |
| US-6242435-B1 | VITAMIN D ANALOG AND A RETINOID | GENTRIX LLC | 2001-06-05 | — | — | US | disclosed |
| US-20010002396-A1 | COMPOSITIONS AND METHODS OF TREATING SKIN CONDITIONS | GENTRIX LLC | 2001-05-31 | — | — | US | disclosed |
| US-6150421-A | Treatment of estrogen-receptor positive breast cancer and estrogen-receptor negative breast cancer with retinoid with CH2 OH at the side chain terminal position | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000003700-A1 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | ACHKAR CHARLES C (US) | 2000-01-27 | — | — | WO | disclosed |
| US-5962534-A | ACNE THERAPY | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999048529-A1 | RETINOID-GLITAZONE COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-30 | — | — | WO | disclosed |
| US-5786391-A | Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position | CORNELL RESEARCH FOUNDATION, INC. (US) | 1998-07-28 | — | — | US | disclosed |
| WO-1996021438-A1 | REGULATING GENE EXPRESSION USING RETINOIDS WITH CH2OH OR RELATED GROUPS AT THE SIDE CHAIN TERMINAL POSITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| US-5489611-A | ADMINISTERING A RETINOID COMPOUND | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| US-4474983-A | Process for preparing compounds having a 1,5-dimethyl-hexa-1,5-dienylene group by desulphonylation of a corresponding sulphone | RHONE-POULENC S.A. (FR) | 1984-10-02 | — | — | US | disclosed |
| US-4433171-A | Sulphones having a 1,5-dimethyl-hexa-1,5-dienylene group | RHONE-POULENC S.A. (FR) | 1984-02-21 | — | — | US | disclosed |
| US-4331814-A | Sulphones having a 1,5-dimethyl-hexa-1,5-dienylene group | RHONE POULENC S.A. (FR) | 1982-05-25 | — | — | US | disclosed |
| US-4209450-A | Introduction of a carbonyl group into a cyclohexene ring | BASK AKTIENGESELLSCHAFT (DE) | 1980-06-24 | — | — | US | disclosed |
| US-4049718-A | Sulphones | RHONE-POULENC, S.A. (FR) | 1977-09-20 | — | — | US | disclosed |
| US-4048234-A | Sulphones | RHONE-POULENC S.A. (FR) | 1977-09-13 | — | — | US | disclosed |
| US-4048234-A | Sulphones | RHONE-POULENC S.A. (FR) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (24 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247549-A1 | Methods of using saha and bortezomib for treating cancer | HDAC5, HDAC6, HDAC4 | MAPT 2839/4885ALOX15 4281/4885ALDH1A1 1702/4885 |
| US-20070197473-A1 | Methods of using SAHA and Bortezomib for treating cancer | HDAC5, HDAC6, HDAC4 | MAPT 2839/4885ALOX15 4281/4885ALDH1A1 1702/4885 |
| US-20160368857-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | MAPT 383/4885ALOX15 1163/4885ALDH1A1 545/4885 |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM3B | MAPT 213/4885ALOX15 658/4885ALDH1A1 307/4885 |
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | MAPT 334/4885ALOX15 1195/4885ALDH1A1 562/4885 |
| US-20090227674-A1 | Combination methods fo saha and targretin for treating cancer | HDAC5, HDAC4, HDAC9 | MAPT 3670/4885ALOX15 1591/4885ALDH1A1 558/4885 |
| US-20010049365-A1 | Vitamin D analog and a retinoid, wherein: the retinoid is 4-oxo-retinol, 4-oxo- retinal, or 4-oxo-retinyl ester; also restoring the natural color of gray hair; treating hair and skin disorders | RBP4, VDR, CYP24A1 | MAPT 4178/4885ALOX15 970/4885ALDH1A1 234/4885 |
| US-20070117815-A1 | Method of treating cancers with SAHA and pemetrexed | HDAC5, HDAC1, HDAC4 | MAPT 2630/4885ALOX15 3733/4885ALDH1A1 588/4885 |
| US-20060281813-A1 | Methods of treating hyperproliferative cell disorders | HRAS, CDC73, MKI67 | MAPT 4706/4885ALOX15 1556/4885ALDH1A1 1302/4885 |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | MAPT 334/4885ALOX15 1195/4885ALDH1A1 562/4885 |
| US-20030207848-A1 | Compositions and methods of treating abnormal cell proliferation | VDR, CYP24A1, CYP2R1 | MAPT 4604/4885ALOX15 1114/4885ALDH1A1 462/4885 |
| US-20070197568-A1 | Methods of using SAHA and Erlotinib for treating cancer | HDAC5, HDAC1, HDAC6 | MAPT 3572/4885ALOX15 3942/4885ALDH1A1 307/4885 |
| US-20080221138-A1 | Method of using SAHA and Erlotinib for treating cancer | HDAC5, HDAC1, HDAC6 | MAPT 3440/4885ALOX15 3806/4885ALDH1A1 312/4885 |
| US-20060287255-A1 | C-linked glucuronide of N-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth | UGT2B17, ALDH1A2, UGT2B7 | MAPT 3977/4885ALOX15 1390/4885ALDH1A1 55/4885 |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM3B | MAPT 213/4885ALOX15 658/4885ALDH1A1 307/4885 |
| US-20090105329-A1 | Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies | HDAC5, HDAC1, HDAC6 | MAPT 1781/4885ALOX15 4001/4885ALDH1A1 612/4885 |
| US-20110212906-A1 | C-LINKED GLUCURONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHODS OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH | ALDH1A2, UGT2B17, UGT2B7 | MAPT 4027/4885ALOX15 1419/4885ALDH1A1 50/4885 |
| US-20100113392-A1 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING MULTIPLE MYELOMA | HDAC5, HDAC4, HDAC6 | MAPT 3004/4885ALOX15 4084/4885ALDH1A1 1856/4885 |
| US-20090304614-A1 | Use of Polyunsaturated Compounds as Whitening Agents | FASN, ALOX5, ALOX15B | MAPT 2405/4885ALOX15 5/4885ALDH1A1 277/4885 |
| US-20080269182-A1 | Method of treating cancers with SAHA and Pemetrexed | HDAC5, HDAC1, HDAC4 | MAPT 2630/4885ALOX15 3733/4885ALDH1A1 588/4885 |
| US-20090215706-A1 | C-LINKED GLUCURONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHOD OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH | UGT2B17, ALDH1A2, UGT2B7 | MAPT 3977/4885ALOX15 1390/4885ALDH1A1 55/4885 |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | MAPT 334/4885ALOX15 1195/4885ALDH1A1 562/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | MAPT 334/4885ALOX15 1195/4885ALDH1A1 562/4885 |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | MAPT 383/4885ALOX15 1163/4885ALDH1A1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.